KNSA Company Profile and Key Details

Q: Who are the executives of KNSA?

Mr. Michael R. Megna CPAChief Accounting Officer & Group Vice President of Fin.Ms. Madelyn ZeylikmanSVice President, Gen. Counsel & Sec.Ms. Mei JangSenior Vice President of Technical OperationsMr. Sanj K. PatelChief Executive Officer & ChairmanMr. Eben TessariSenior Vice President & Chief Operating OfficerRachel FrankAssociate Director of Investor RelationsMs. Melissa MannoSenior Vice President & Chief HR OfficerDr. John F. PaoliniSenior Vice President & Chief Medical OfficerMr. Chad MorinSVice President, Chief Compliance Officer & Head of QualityMr. Mark Ragosa C.F.A.Senior Vice President & Chief Financial Officer

NASDAQ : KNSA

Kiniksa Pharmaceuticals

$52.30

-0.04-0.08%

At Close 4:00 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kiniksa Pharmaceuticals, Ltd. (KNSA) stock declined over -0.08%, trading at $52.30 on NASDAQ, down from the previous close of $52.34. The stock opened at $52.22, fluctuating between $51.08 and $52.44 in the recent session.

Stock Snapshot

52.34

Prev. Close

3.93B

Market Cap

51.0752

Day Low

57.47

P/E Ratio

0.91

EPS (TTM)

Cash Flow per Share

52.22

Open

75.17M

Number of Shares

52.44

Day High

95.61%

Free Float in %

0.01

Book Value

366.55K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 16, 2026	52.20	52.44	51.08	52.30	372.07K
Jun 15, 2026	51.75	53.28	51.70	52.34	627.22K
Jun 12, 2026	51.66	52.48	51.36	51.89	360.96K
Jun 11, 2026	49.20	51.64	48.71	51.58	622.35K
Jun 10, 2026	48.64	50.09	48.51	49.27	462.71K
Jun 09, 2026	49.68	50.72	48.49	48.70	514.8K
Jun 08, 2026	48.80	49.40	47.95	49.04	443.89K
Jun 05, 2026	48.98	49.99	48.21	48.42	341.55K
Jun 04, 2026	47.98	50.48	47.43	49.23	470.22K
Jun 03, 2026	47.41	48.44	47.24	47.85	489.25K
Jun 01, 2026	47.84	48.94	46.63	48.43	748.32K
May 29, 2026	50.72	50.80	48.06	48.38	722.07K
May 28, 2026	52.00	52.01	50.72	50.84	486.55K
May 27, 2026	52.71	53.37	51.50	51.84	611.08K
May 26, 2026	53.24	53.63	52.26	52.86	550.6K
May 22, 2026	53.48	55.08	53.02	53.24	377.75K
May 21, 2026	53.59	55.33	53.16	53.65	767.59K
May 20, 2026	53.59	54.51	52.31	54.28	447.3K
May 19, 2026	53.50	54.28	52.93	53.34	452.61K
May 18, 2026	56.95	57.01	53.31	53.64	535.51K

Contact Details

Hamilton, HM 11

Bermuda

https://www.kiniksa.com 781 439 9100

About Company

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Stock Peers

ARGX

-5.71-0.65%

argenx SE$878.49 REGN

-0.25-0.04%

Regeneron Pharmaceuticals, Inc.$614.73 UTHR

-1.3-0.24%

United Therapeutics Corporation$548.27 MDGL

1.43+0.29%

Madrigal Pharmaceuticals, Inc.$501.19 VRTX

2.71+0.60%

Vertex Pharmaceuticals Incorporated$453.17 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-1.38-0.42%

Krystal Biotech, Inc.$323.37 ALNY

-5.9-2.05%

Alnylam Pharmaceuticals, Inc.$281.90 PRAX

-7.29-2.76%

Praxis Precision Medicines, Inc.$257.25 LGND

2+0.79%

Ligand Pharmaceuticals Incorporated$255.25

Frequently Asked Questions

What is the current Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) stock price is $52.30 in the last trading session. During the trading session, KNSA stock reached the peak price of $52.44 while $51.08 was the lowest point it dropped to. The percentage change in KNSA stock occurred in the recent session was -0.08% while the dollar amount for the price change in KNSA stock was - $0.04.

KNSA's industry and sector of operation?

The NASDAQ listed KNSA is part of Biotechnology industry that operates in the broader Healthcare sector. Kiniksa Pharmaceuticals, Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KNSA?

Mr. Michael R. Megna CPA
Chief Accounting Officer & Group Vice President of Fin.
Ms. Madelyn Zeylikman
SVice President, Gen. Counsel & Sec.
Ms. Mei Jang
Senior Vice President of Technical Operations
Mr. Sanj K. Patel
Chief Executive Officer & Chairman
Mr. Eben Tessari
Senior Vice President & Chief Operating Officer
Rachel Frank
Associate Director of Investor Relations
Ms. Melissa Manno
Senior Vice President & Chief HR Officer
Dr. John F. Paolini
Senior Vice President & Chief Medical Officer
Mr. Chad Morin
SVice President, Chief Compliance Officer & Head of Quality
Mr. Mark Ragosa C.F.A.
Senior Vice President & Chief Financial Officer

How KNSA did perform over past 52-week?

KNSA's closing price is 99.09% higher than its 52-week low of $26.27 where as its distance from 52-week high of $59.87 is -12.64%.

How many employees does KNSA have?

Number of KNSA employees currently stands at 315.

Link for KNSA official website?

Official Website of KNSA is: https://www.kiniksa.com

How do I contact KNSA?

KNSA could be contacted at phone 781 439 9100 and can also be accessed through its website. KNSA operates from Clarendon House, Hamilton, HM 11, Bermuda.

How many shares of KNSA are traded daily?

KNSA stock volume for the day was 366.55K shares. The average number of KNSA shares traded daily for last 3 months was 662.86K.

What is the market cap of KNSA currently?

The market value of KNSA currently stands at $3.93B with its latest stock price at $52.30 and 75.17M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	315
Beta	0.09
Sales or Revenue	$270.26M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	315
Beta	0.09
Sales or Revenue	$270.26M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KNSA Company Profile and Key Details

Kiniksa Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook